8:20 am Chairperson’s Opening Remarks
Showcasing Game-Changing ADCs With a View to Moving ADCs into Earlier Line Treatments to Improve Patient Outcomes Sooner
8:30 am Development of ENHERTU, An HER2-directed Dxd ADC, In Early Breast Cancer & Beyond
Synopsis
- Discussing Destiny-Breast03, a Phase 3 randomised study of ENHERTU versus T-DM1 in patients with HER2+ metastatic breast cancer
- Reviewing plans to develop ENHERTU in early breast cancer
- Describing plans to expand the development of ENHERTU in gastric cancer, NSCLC and other tumours
9:00 am ADC Therapeutic Window Enhancement Based on the AJICAP Chemical Site-Specific Conjugation Platform
Synopsis
- Examining how site-specific technologies are being employed in many of the next-generation ADCs due to enhancement of clinically-relevant biological properties observed in various preclinical studies
- Demonstrating a novel method of affinity peptide mediated regiodivergent antibody functionalisation that enables the synthesis of ADCs from native IgGs in a tunable and atom-precise manner
- Highlighting how both thiol-based and azide-based site-specific ADCs produced by “AJICAP” technology demonstrated an expansion of their therapeutic index compared with stochastic technology
9:30 am Exploring Tisotumab Vedotin in Frontline Cervical Cancer
Synopsis
- Showcasing Tisotumab Vedotin data from the innovaTV 204 clinical trial
- Discussing emerging Tisotumab Vedotin data as a frontline treatment
- Exploring how Tisotumab Vedotin has the possibility as a frontline treatment for cervical cancer
10:00 am
Morning Break
1:00 pm
Lunch & Networking
Delving into the Development of Antibody Drug Conjugates with Novel Modes of Action
2:00 pm Antibody-mediated Delivery of Protein Degraders
Synopsis
- Sharing efforts to expand ADC technology outside of pan-cytotoxics
- Evaluating the impact of DAR and payload potency on ADC activity
- Optimising linker-drug structure for PK
2:30 pm Modulating the Therapeutic Activity of ADCs & SMDCs With Engineered Cytokine Products
Synopsis
- Understanding how the therapeutic activity of ADCs and SMDCs can be potentiated with certain antibody-cytokine fusion proteins
- Illustrating how antibody-cytokine fusions, based on interleukin-2 and capable of selective localisation at the tumour site, are particularly effective in boosting the activity of ADCs and SMDCs
- Discussing the role of NK cells and of T cells
3:00 pm Designing Immune-Stimulating Antibody Conjugates
Synopsis
- Overview of Bolt’s Immune-Stimulating Antibody Conjugates (ISAC) technology platform as the next step in ADC-based immune therapy
- Highlighting the key features and the mechanism of action
- Demonstrating the use of various methods to understand and design potent ISACs
3:30 pm
Afternoon Refreshments
Analysing Innovative Technologies to Progress the Next Generation of ADCs
4:00 pm Novel In Vitro Screening Assays for ADC Characterisation & Stability Assessment
Synopsis
- Exploring new approaches to characterise ADCs In Vitro
- Outlining how this technology can be leveraged to design best-in-class ADCS
4:30 pm Bicycle Conjugates to Target Solid Tumours
Synopsis
- Bicycles, constrained bicyclic peptides, offer antibody-like affinity and selectivity in a small molecule format
- Bicycle Toxin Conjugates are now in clinical development, offering rapid tumour penetration with limited plasma exposure
- Discover how Bicycles can be used to stimulate Immuno-oncology targets such as CD137, which can be targeted to tumour cells using Bicycle tumour-targeted immune cell agonising molecules (TICAs™)